Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 365-370

  Tanaka, Masatake ^a   Masaki, Yuko ^a   Tanaka, Kosuke ^a   Miyazaki, Masayuki ^a   Kato, Masaki ^a   Sugimoto, Rie ^b   Nakamura, Kazuhiko ^a   Aishima, Shinichi ^a   Shirabe, Ken ^a   Nakamuta, Makoto ^c   Enjoji, Munechika ^d   Kotoh, Kazuhiro ^a   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cancer metabolism; Differentiation; Epithelial mesenchymal transition; Fatty acid oxidation; Hepatocellular carcinoma; Hypoxia; Hypoxia inducible factor; Metastasis; Pyruvate kinase

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; ACYL COENZYME A OXIDASE; FATTY ACID; MESSENGER RNA; PYRUVATE KINASE; TRANSCRIPTION FACTOR ETS 1; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL DEDIFFERENTIATION; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HYPOXIA; LIVER CELL CARCINOMA; MALE; METASTASIS; REDUCTION; SYNTHESIS; TUMOR DIFFERENTIATION;

3-HYDROXYACYL COA DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FATTY ACIDS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OXIDATION-REDUCTION; OXIDOREDUCTASES; PROTO-ONCOGENE PROTEIN C-ETS-1; RNA, MESSENGER; THYROID HORMONES; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873820273     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1201     Document Type: Article

References (54)

1. Li L, Zhang J, Liu X, Li X, Jiao B and Kang T: Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J Gastroenterol Hepatol 27: 51-58, 2012.
2. Tiong L and Maddern GJ: Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for hepatocellular carcinoma. Br J Surg 98: 1210-1224, 2011.
3. Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ and Lam VW: Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford) 14: 285-290, 2012.
4. Hasegawa K and Kokudo N: Surgical treatment of hepatocellular carcinoma. Surg Today 39: 833-843, 2009.
5. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A and Bolondi L: Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 22: 391-398, 2010.
6. Wiedmann MW and Mossner J: Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. Curr Cancer Drug Targets 11: 714-733, 2011.
7. Pandey PR, Liu W, Xing F, Fukuda K and Watabe K: Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Pat Anticancer Drug Discov 7: 185-197, 2012.
8. Romero-Garcia S, Lopez-Gonzalez JS, Baez-Viveros JL, Aguilar-Cazares D and Prado-Garcia H: Tumor cell metabolism: an integral view. Cancer Biol Ther 12: 939-948, 2011.
9. Dang CV: Links between metabolism and cancer. Genes Dev 26: 877-890, 2012.
10. de Souza AC, Justo GZ, de Araujo DR and Cavagis AD: Defining the molecular basis of tumor metabolism: a continuing challenge since Warburg's discovery. Cell Physiol Biochem 28: 771-792, 2011.
11. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233, 2008.
12. Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452: 181-186, 2008.
13. Flavin R, Peluso S, Nguyen PL and Loda M: Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6: 551-562, 2010.
14. Kridel SJ, Lowther WT and Pemble CW IV: Fatty acid synthase inhibitors: new directions for oncology. Expert Opin Investig Drugs 16: 1817-1829, 2007.
15. Litwin JA, Beier K, Volkl A, Hofmann WJ and Fahimi HD: Immunocytochemical investigation of catalase and peroxisomal lipid beta-oxidation enzymes in human hepatocellular tumors and liver cirrhosis. Virchows Arch 435: 486-495, 1999.
16. Okuda K: Hepatocellular carcinoma: clinicopathological aspects. J Gastroenterol Hepatol 12: S314-S318, 1997.
17. Qin LX and Tang ZY: The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 8: 193-199, 2002.
18. Trevisani F, Cantarini MC, Wands JR and Bernardi M: Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 29: 1299-1305, 2008.
19. Kim SH, Lim HK, Choi D, Lee WJ, Kim MJ, Kim CK, Jeon YH, Lee JM and Rhim H: Percutaneous radiofrequency ablation of hepatocellular carcinoma: effect of histologic grade on therapeutic results. AJR Am J Roentgenol 186 (Suppl 5): S327-S333, 2006.
20. Yao D, Dai C and Peng S: Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 9: 1608-1620, 2011.
21. Gomes LR, Terra LF, Sogayar MC and Labriola L: Epithelial-mesenchymal transition: implications in cancer progression and metastasis. Curr Pharm Biotechnol 12: 1881-1890, 2011.
22. Qin LX and Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 130: 497-513, 2004.
23. Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, Wu W, Qiu LW and Meng XY: Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 4: 220-226, 2005.
24. Feng DY, Shen M, Zheng H and Cheng RX: Relationship between vascular endothelial growth factor expression and microvessel density in hepatocellular carcinomas and their surrounding liver tissue. Hunan Yi Ke Da Xue Xue Bao 25: 132-134, 2000 (In Chinese).
25. Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 7: 462-503, 1954.
26. Becker KF, Rosivatz E, Blechschmidt K, Kremmer E, Sarbia M and Hofler H: Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs 185: 204-212, 2007.
27. Haraguchi M: The role of the transcriptional regulator snail in cell detachment, reattachment and migration. Cell Adh Migr 3: 259-263, 2009.
28. Kajdaniuk D, Marek B, Foltyn W and Kos-Kudla B: Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology. Endokrynol Pol 62: 444-455, 2011.
29. Ferrara N, Houck K, Jakeman L and Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32, 1992.
30. Sato Y, Teruyama K, Nakano T, Oda N, Abe M, Tanaka K and Iwasaka-Yagi C: Role of transcription factors in angiogenesis: Ets-1 promotes angiogenesis as well as endothelial apoptosis. Ann N Y Acad Sci 947: 117-123, 2001.
31. Dittmer J: The biology of the Ets1 proto-oncogene. Mol Cancer 2: 29, 2003.
32. Frain M, Swart G, Monaci P, Nicosia A, Stampfli S, Frank R and Cortese R: The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 59: 145-157, 1989.
33. Taraviras S, Monaghan AP, Schutz G and Kelsey G: Characterization of the mouse HNF-4 gene and its expression during mouse embryogenesis. Mech Dev 48: 67-79, 1994.
34. Faust DM, Boshart M, Imaizumi-Scherrer T, Schutz G and Weiss MC: Constancy of expression of the protein kinase A regulatory subunit R1 alpha in hepatoma cell lines of different phenotypes. Cell Growth Differ 5: 47-53, 1994.
35. Yokoyama Y, Kuramitsu Y, Takashima M, Iizuka N, Toda T, Terai S, Sakaida I, Oka M, Nakamura K and Okita K: Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics 4: 2111-2116, 2004.
36. Suto K, Kajihara-Kano H, Yokoyama Y, Hayakari M, Kimura J, Kumano T, Takahata T, Kudo H and Tsuchida S: Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas. J Cancer Res Clin Oncol 125: 83-88, 1999.
37. Yang SH, Watanabe J, Nakashima O and Kojiro M: Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Int 46: 503-509, 1996.
38. Koopman WJ, Nijtmans LG, Dieteren CE, Roestenberg P, Valsecchi F, Smeitink JA and Willems PH: Mammalian mitochondrial complex I: biogenesis, regulation, and reactive oxygen species generation. Antioxid Redox Signal 12: 1431-1470, 2010.
39. Pelicano H, Carney D and Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004.
40. Altenberg B and Greulich KO: Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004.
41. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
42. Tani K, Yoshida MC, Satoh H, Mitamura K, Noguchi T, Tanaka T, Fujii H and Miwa S: Human M2-type pyruvate kinase: cDNA cloning, chromosomal assignment and expression in hepatoma. Gene 73: 509-516, 1988.
43. Hacker HJ, Steinberg P and Bannasch P: Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19: 99-107, 1998.
44. Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y, Yamanaka K, Nagata H, Taura K, Yasuchika K, Nitta T and Uemoto S: Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 55: 846-857, 2011.
45. Ahluwalia A and Tarnawski AS: Critical role of hypoxia sensor - HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 19: 90-97, 2012.
46. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, Cole RN, Pandey A and Semenza GL: Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 145: 732-744, 2011.
47. Oikawa M, Abe M, Kurosawa H, Hida W, Shirato K and Sato Y: Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem Biophys Res Commun 289: 39-43, 2001.
48. Miyoshi A, Kitajima Y, Ide T, Ohtaka K, Nagasawa H, Uto Y, Hori H and Miyazaki K: Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1α-independent manner. Int J Oncol 29: 1533-1539, 2006.
49. Salnikow K, Aprelikova O, Ivanov S, Tackett S, Kaczmarek M, Karaczyn A, Yee H, Kasprzak KS and Niederhuber J: Regulation of hypoxia-inducible genes by ETS1 transcription factor. Carcinogenesis 29: 1493-1499, 2008.
50. Ciruna B and Rossant J: FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak. Dev Cell 1: 37-49, 2001.
51. Thuault S, Tan EJ, Peinado H, Cano A, Heldin CH and Moustakas A: HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to- mesenchymal transition. J Biol Chem 283: 33437-33446, 2008.
52. Wanami LS, Chen HY, Peiro S, Garcia de Herreros A and Bachelder RE: Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression. Exp Cell Res 314: 2448-2453, 2008.
53. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T and Konishi I: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 163: 1437-1447, 2003.
54. Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA and Ohh M: VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27: 157-169, 2007.